Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · PGHL

PGHL

HealthcarePharmaceuticals & Biotechnology₹9135 cr market cap
₹5536.50 ▲ +0.57% today As of 19 Nov 2026
52-week low ₹4778.6052-week high ₹6918.50

-20.4% from the 52-week high · +15.2% above the low

Procter & Gamble Health Ltd. engages in the manufacture and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company’s brands include Cosome, Evion, Neurobion, Seven Seas, Nasivion, Polybion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Evion range has different variants with different levels of Vitamin E, such as Evion 400, Evion 200, and Evion 600. Neurobion offers a range of neurotropic B-Vitamins which are a combination to help treat nerve damage and regenerate the nerves to relieve symptoms. Nasivion Classic Nasal Spray starts working on a blocked nose in 25 seconds. Polybion is a brand that helps with release and hence supports an active life.

The short version. Promoter holding was 51.82% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

PGHL trades 20.4% below its 52-week high and 15.2% above its 52-week low.

Change over period: —

1M+7.2%
3M-4.8%
6M+2.7%
1Y-6.5%

4 · The owners

Who holds it, and are they adding?

Promoter holding51.82%

Unchanged over 8 quarters.

Foreign institutions6.42%

Down 0.6 pts over 8 quarters.

Domestic institutions12.63%

Down 2.08 pts over 8 quarters.

Mutual fund schemes30

+6 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter51.8251.8251.8251.8251.8251.8251.8251.820.0
FII7.026.876.997.246.976.26.336.42-0.6
DII14.7114.2114.1613.9113.8413.6712.4412.63-2.08
Public26.4627.1127.0327.0427.3728.3129.4229.13+2.67

Mutual fund holdings · Oct 2026

30 schemes hold this stock

24 the month before.

  • UTI - MNC Fund4.25% of NAV
  • Sundaram Long Term Tax Advantage Fund Series IV3.56% of NAV
  • Sundaram Long Term Tax Advantage Fund Series III3.19% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series VI3.15% of NAV
  • TATA INDIA PHARMA & HEALTHCARE FUND3.15% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series V3.14% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series III2.99% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series IV2.95% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for PGHL are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about PGHL

What is the PGHL share price?

PGHL (PGHL) last closed at ₹5,536.50, up 0.57% on the day. Its 52-week range is ₹4,778.60 to ₹6,918.50.

What is the market cap of PGHL?

PGHL has a market capitalisation of about ₹9,135 crore. Its price-to-earnings ratio is 26.4.

How are PGHL's latest results?

Promoter holding was 51.82% in Sep 2026, up 0.00 points over 8 quarters.

Who owns PGHL?

As of Sep 2026, shareholding was: Promoter 51.82%, FII 6.42%, DII 12.63%, Public 29.13%.

How many mutual funds hold PGHL?

30 mutual fund schemes held PGHL in October 2026. That compares with 24 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 12 Feb 2026 · Interim Dividend - Rs. 110
  • 12 Feb 2026 · Special Dividend - Rs. 50
  • 22 Aug 2025 · Final Dividend - Rs. 45
  • 21 Feb 2025 · Interim Dividend - Rs. 80
  • 28 Nov 2024 · Final Dividend - Rs. 60
  • 14 Feb 2024 · Special Dividend - Rs. 150

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.